摘要
目的探讨红花对局灶节段性肾小球硬化(FSGS)大鼠纤溶酶原激活物(t-PA)及纤溶酶原激活物抑制物-1(PAI-1)的干预作用。方法40只SD大鼠随机分为假手术组、模型组、缬沙坦组和红花组,每组10只,除假手术组外,其余3组用一侧肾切除加尾静脉注射阿霉素的方法复制FSGS大鼠模型,同时,第1次尾静脉注射1周后红花组灌服红花4g/kg.d;缬沙坦组灌服缬沙坦10 mg/kg.d。8周末采用酶联免疫吸附法(ELISA)测定血t-PA、PAI-1的含量,并进行光镜检查。结果各组之间t-PA的含量无明显差异(P>0.05)。模型组PAI-1含量与假手术组相比明显升高(P<0.01);缬沙坦组、红花组与模型组比较PAI-1含量明显降低(P<0.01),缬沙坦组与红花组之间无明显差异(P>0.05)。结论FSGS模型大鼠存在着PAI-1的高表达,红花能减少血PAI-1的表达,纠正纤溶系统的紊乱,延缓其病理进程。
Objective To survey the effect of Honghua on blood t - PA and PAI- 1 in Focal Segmental Golmeruloselerosis (FSGS) rats. Methods 40 SD male rats were divided into four groups:sham operation group, model group, Valsartan group and HongHua group. Each animal adopted one side nephreetomy and tail intravenous injection of A driamyein except Sham group. Drugs were administered from the seventh day after operation. The expression of t - PA and PAI- 1 was detected by ELISA and the pathological change was observed. Results There had no significant differences for the relative content of t - PA between each group (P 〉 0.05 ). The relative content of PAI- 1 in model group was significantly higher than that of sham group (P 〈 0.01 ), and the contents in Valsartan group and Honghua group were significantly lower than that in model group(P 〈 0.01 ) , but there was no significant difference between Valsartan group and Honghua group. Conclusion The expression of PAI- 1 is high in FSGS rats. Honghua can retrieve the expression of PAI - 1 and adjust the unbalance of t - PA and PAI- 1, reduce the lesion of pathology.
出处
《时珍国医国药》
CAS
CSCD
北大核心
2008年第9期2217-2218,共2页
Lishizhen Medicine and Materia Medica Research
关键词
红花
局灶节段性肾小球硬化
纤溶系统
Honghua
FSGS
Activator of plasminogen
Plasminogen activator inhibitor